Ignite Creation Date:
2025-12-25 @ 2:22 AM
Ignite Modification Date:
2026-03-02 @ 9:08 PM
Study NCT ID:
NCT01828034
Status:
COMPLETED
Last Update Posted:
2020-11-17
First Post:
2013-04-05
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-04
Start Date Type:
ACTUAL
Primary Completion Date:
2019-05-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-05-30
Completion Date Type:
ACTUAL
First Submit Date:
2013-04-05
First Submit QC Date:
None
Study First Post Date:
2013-04-10
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-04-27
Results First Submit QC Date:
None
Results First Post Date:
2020-11-17
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-10-26
Last Update Post Date:
2020-11-17
Last Update Post Date Type:
ACTUAL